홈 › 비소세포폐암 › 매사추세츠 › Worcester
MA Worcester의 비소세포폐암 임상 시험
비소세포폐암 관련 연구 14개가 Worcester 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
피험자 모집 중3상
- UMass Memorial Medical Center - University Campus, Worcester
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
피험자 모집 중3상
- University of Massachusetts Memorial Medical Center, Worcester
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
피험자 모집 중3상
- UMass Memorial Medical Center - University Campus, Worcester
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
피험자 모집 중3상
- University of Massachusetts Worcester, Worcester
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
피험자 모집 중3상
- Reliant Medical Group Inc, Worcester
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
피험자 모집 중3상
- Reliant Medical Group, Worcester
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
피험자 모집 중3상
- Clinical Study Site, Worcester
- Clinical Study Site, Milford · 17마일 거리
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
피험자 모집 중2/3상
- Dana-Farber Brigham and Womens Cancer Center at Milford Regional, Milford · 17마일 거리
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
피험자 모집 중3상
- University of Massachusetts Memorial Medical Center, Worcester
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
피험자 모집 중2상
- UMass Memorial Medical Center - University Campus, Worcester
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
피험자 모집 중2상
- UMass Memorial Medical Center - University Campus, Worcester
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
피험자 모집 중2상
- UMass Memorial Medical Center - University Campus, Worcester
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
피험자 모집 중2/3상
- UMass Memorial Medical Center - University Campus, Worcester
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
피험자 모집 중관찰 연구
- Massive Bio SYNERGY-AI site, Worcester
다른 도시의 비소세포폐암 시험
- Houston, TX연구 145개
- New York City, NY연구 120개
- Arlington, VA연구 104개
- Nashville, TN연구 97개
- Boston, MA연구 90개
- Los Angeles, CA연구 87개
- St. Louis, MO연구 73개
- Chicago, IL연구 61개
- Baltimore, MD연구 60개
- San Antonio, TX연구 59개
- Columbus, OH연구 56개
- Washington, DC연구 55개
Worcester의 다른 연구
- 폐암연구 11개
- 암 (전체)연구 7개
- 유방암연구 6개
- 조현병연구 5개
- 전이성 암연구 5개
- 전립선암연구 5개
- 난소암연구 5개
- 주요우울장애연구 5개
- 우울증연구 5개
- 급성 골수성 백혈병연구 5개
- 요로상피(이행상피)암연구 4개
- 방광암연구 4개
ClinicalTrials.gov 출처, 2026. 10. 5. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.